PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults
- Conditions
- AgingFrail Older Adults
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT00527046
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00527150
- Locations
- 🇺🇸
Pfizer Investigational Site, Fargo, North Dakota, United States
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- Drug: CP-464,005
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00527397
- Locations
- 🇯🇵
Pfizer Investigational Site, Tokyo, Japan
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
- Conditions
- Influenza
- Interventions
- Biological: 13 valent pneumococcal conjugate vaccine
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT00521586
- Locations
- 🇺🇸
Accelovance, Peoria, Illinois, United States
🇺🇸FFM Clinical Research, Camillus, New York, United States
🇺🇸Rochester Clinical Research, Rochester, New York, United States
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00511849
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
- Conditions
- Migraine
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT00510419
- Locations
- 🇺🇸
New England Center for Headache, Stamford, Connecticut, United States
🇺🇸Diamond Head Clinic, Chicago, Illinois, United States
🇺🇸Clinvest, Springfield, Missouri, United States
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
- Conditions
- Hormone Refractory Prostate CancerProstate Cancer
- Interventions
- Drug: MDV3100
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT00510718
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸Investigational Pharmacy Services, Houston, Texas, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent Pneumococcal Conjugate VaccineBiological: 7 valent pneumococcal conjugate vaccine
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1866
- Registration Number
- NCT00508742
- Locations
- 🇮🇱
Pfizer Investigational Site, Segev Shalom, Israel
🇮🇱Pfizer Investigational Sites (7), Beer-Sheva, Israel
Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay
- Conditions
- Healthy
- Interventions
- Procedure: Large volume blood draw
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 152
- Registration Number
- NCT00508950
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Secaucus, New Jersey, United States
A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak
- Conditions
- Postherpetic Neuralgia
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00506610
- Locations
- 🇺🇸
Plains Medical Clinic, Fargo, North Dakota, United States
🇺🇸Odyssey Research, Spokane, Washington, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States